AstraZeneca’s (AZN.L) hopes of topping $45 billion in revenue by 2023 have been dealt a blow by a problem with an experimental psoriasis drug that the drugmaker had viewed as a potential billion-dollar plus seller.    Amgen (AMGN.O), its partner on the project, announced late on Friday it was ending a collaboration to develop brodalumab […]

Two powerful and innovative cholesterol drugs likely to be approved this summer both target the same protein and have been shown to sharply lower LDL in high-risk patients.  But there is at least one significant difference between the two offerings: the dosages in which they will be sold.   Assuming approval from the U.S. Food […]

THOUSAND OAKS, Calif., May 22, 2015 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the Company has commenced termination of its participation in the co-development and commercialization of brodalumab with AstraZeneca (LON:AZN, STO:AZN and NYSE:AZN). Brodalumab, an investigational IL-17 inhibitor, is in development for patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis. The decision was […]

UNIVERSITY PARK, Pa. — An association between resting heart rate and diabetes suggests that heart rate measures could identify individuals with a higher future risk of diabetes, according to an international team of researchers. In a four-year study of 73,357 Chinese adults, researchers observed that faster heart rates were positively associated with an increased risk […]

SUNNYVALE, Calif., May 22, 2015 /PRNewswire/ — Pharmacyclics, Inc. (NASDAQ: PCYC) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending a change to the terms of the marketing authorization for IMBRUVICA® (ibrutinib) in the European Union to indicate the treatment of adult […]

  German drugmaker Bayer expects the world’s largest economies to pool billions of euros in funding for the development of antibiotics against the growing threat of drug-resistant superbugs, its chief executive said on Friday.   “I expect a multinational fund for antibiotics research. One country alone can’t shoulder it,” CEO Marijn Dekkers told Germany’s Der […]

Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop a psoriasis drug after it observed suicidal thoughts in the subjects of a trial.   Amgen said such safety concerns would likely result in a restrictive label that could limit the number of patients using the late-stage experimental drug, brodalumab. The company […]

  Amgen Inc’s closely watched new cholesterol drug, Repatha, has been recommended for approval in Europe, putting the U.S. drugmaker ahead in a race with rival Sanofi SA. Repatha, or evolocumab, belongs to a new class of cholesterol-lowering drugs known as PCSK9 inhibitors that have the potential to drastically reduce the risk of heart attacks when used […]

European regulators have recommended approval of Merck & Co Inc’s immune system-boosting cancer drug Keytruda, following a similar green light last month for Bristol-Myers Squibb Co’s rival product Opdivo. Merck’s drug, also known as pembrolizumab, was endorsed on Friday by the European Medicines Agency (EMA) for the treatment of melanoma. Both Keytruda and Opdivo are […]

Entresto. That’s the brand name Novartis has chosen for LCZ696, its new heart failure drug that is expected to be a blockbuster. The name won’t be final until official confirmation, which comes with FDA approval. But Novartis will introduce the name for the first time this weekend in presentations at the European Society of Cardiology Heart Failure meeting in Seville, […]